Trial Profile

CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients With Klebsiella Pneumoniae OXA-48 or Pseudomonas Aeruginosa Infections: A Single-center Randomized Open-label Trial (ZAVICONT)

Status: Not yet recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avibactam/ceftazidime (Primary)
Indications Gram-negative infections; Infections; Klebsiella infections; Pseudomonal infections
Focus Therapeutic Use
Acronyms ZAVICONT

22 Apr 2025 Planned End Date changed from 1 Feb 2027 to 1 Aug 2027.
22 Apr 2025 Planned primary completion date changed from 1 Jan 2027 to 1 May 2027.
22 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 1 May 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com